As per the letter enclosed.
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr Agarwals Eye Hospital reported Q2 FY26 revenue from operations of ₹117.72 Cr, up about 15% YoY from ₹102.19 Cr. Net profit surged roughly 36% YoY to ₹19.32 Cr, while EBITDA rose to ₹40.76 Cr with margins expanding to ~34.6% from ~31.5% a year earlier. For the first half of FY26, revenue grew 16% to ₹234.64 Cr and net profit climbed 29% to ₹36.58 Cr. The board declared an interim dividend of ₹3 per share (30%) with record date November 7, 2025. The newly appointed statutory auditor S.R. Batliboi & Associates LLP issued a clean (unmodified) limited review report, noting that prior period figures were reviewed by the predecessor auditor.
Strong profit growth and expanding EBITDA margins reflect healthy operating leverage, which is positive for shareholders. The 30% interim dividend offers near-term income support, though investors should track the new auditor's transition.